Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06635590

Chronic Kidney Disease, Hyperkalemia and Echocardiographic Changes

Patients with CKD ( eGFR < <60 mL/min/1,73 m2) presenting to emergency department with isolated hyperkalemia will be study population. Pre and post treatment ECG and echocardiographic findings will be recorded. Investigator will not intervene with the treatment decision of responsible physician and will not delay any intervetion or treatment for the sake of study.

Data will be compared in terms of ECHO and ECG findings depending on hyperkalemia level and response to treatment.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Etlik City Hospital

Ankara, 06170, Turkey (Türkiye)

Location status: Recruiting

Location contact

Bedriye Muge SONMEZ, ass.prof

SUB_INVESTIGATOR

Emre CAKAR, Resident

CONTACT

[email protected]

+905324940295

Emre CAKAR, Resident

SUB_INVESTIGATOR

Gulsen AKCAY, Associate Professor

CONTACT

[email protected]

+905052874949

Gulsen AKCAY, Associate Professor

PRINCIPAL_INVESTIGATOR

Melih GOKCIMEN, specialist

SUB_INVESTIGATOR

Murat OZDEMIR, specialist

SUB_INVESTIGATOR

Suleyman KAYISOGLU, Resident

SUB_INVESTIGATOR

About this study

In this study, the ECG and echocardiography (ECHO) findings in patients with chronic kidney failure who present to the Etlik City Hospital Emergency Medicine Department will be recorded and compared with literature. Echocardiography is a rapid, reliable, and non-invasive examination widely used by physicians for the monitoring of critically ill patients in emergency departments and intensive care units worldwide.

For patients with known chronic kidney failure brought to the emergency department, a blood sample (blood gas and/or biochemistry) will be taken for potassium measurement. Subsequently, an ECG, which is a quick and non-invasive test, will be performed, followed by an ECHO, also a quick and non-invasive test, conducted by an experienced physician. The physician performing the ECHO will not be involved in the treatment process. ECG and ECHO findings will be recorded and compared before and after treatment. Patient mortality will be monitored at 24 hours, 7 days, and 30 days, and other causes of mortality will be excluded. The relationship between ECG and ECHO findings and mortality will be statistically investigated.

Based on the premise that hyperkalemia can cause cardiac arrest during diastole, it is hypothesized that there may be right ventricular enlargement in patients with ECG findings indicative of hyperkalemia. In animal studies, echocardiography results during resuscitation have shown right ventricular enlargement in animals with hyperkalemia. Based on this information, we believe that echocardiography findings in hyperkalemic patients may be associated with mortality, and that the combined use of echocardiography and ECG may be effective in predicting mortality

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients over 18 years old
  • Chronic kidney disease patients with eGFR < 60 mL/min/1.73 m²
  • Patients with hyperkalemia detected in the emergency department
  • Patients willing to participate in the study and who sign the consent form

Exclusion criteria

  • Patients under 18 years old
  • Patients who do not wish to participate in the study
  • Patients without chronic kidney damage
  • Patients without detected hyperkalemia
  • Patients needing cardiopulmonary resuscitation due to hyperkalemia

Treatment and study plan

Primary outcomes

  1. ECHO changes

    Time frame: from enrollment to the end of follow up duration of 30 days

    Describing echocardiograhic (ECHO) changes of isolated hyperkalemia in patients with chronic kidney disease (CKD)

Study contacts

Contact information is provided by the study sponsor or research team.

Emre CAKAR, Resident

CONTACT

[email protected]

+905324940295

Gulsen AKCAY, Ass. Prof.

CONTACT

[email protected]

+905052874949

Sponsors and collaborators

Lead sponsor

Saglik Bilimleri Universitesi

Other

Registry information

Official study title

The Impact of Hyperkalemia-Induced ECG and ECHO Findings on Early and Late Mortality in Patients With Chronic Kidney Disease

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 10, 2024
Registry last updated
Oct 10, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.